Shire Human Genetic Therapies Inc. ; est. no. 1593

205 Alewife Brook Parkway, Cambridge, MA 02138; formerly Transkaryotic Therapies, Inc. (TKT), which was acquired in April 2005 by Shire Pharmaceuticals Group plc for ~$1.6 billion